Mizuho Securities Sticks to Its Buy Rating for Harmony Biosciences Holdings (HRMY)

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Harmony Biosciences Holdings (HRMYResearch Report) today and set a price target of $64.00. The company’s shares closed last Tuesday at $50.60.

According to TipRanks.com, Suvannavejh is a 3-star analyst with an average return of 1.0% and a 49.0% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Intra-Cellular Therapies, and Bioxcel Therapeutics.

Currently, the analyst consensus on Harmony Biosciences Holdings is a Strong Buy with an average price target of $59.50.

See today’s best-performing stocks on TipRanks >>

Based on Harmony Biosciences Holdings’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $85.31 million and net profit of $21.49 million. In comparison, last year the company earned revenue of $59.67 million and had a net profit of $7.39 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.

Read More on HRMY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More